FGF-based Therapeutic
Diabetic Wounds / Severe Ischemic Heart Disease / Peripheral Artery Disease
Key Facts
About Venturis Therapeutics
Venturis Therapeutics is a private, clinical-stage biotech company leveraging Fibroblast Growth Factor (FGF) proteins to promote blood vessel growth for treating ischemic conditions. Its lead program targets diabetic wounds, coronary heart disease, and peripheral artery disease, with a broader preclinical pipeline exploring applications in erectile dysfunction, stroke, and neurodegenerative diseases. Founded in 2021 and headquartered in Cambridge, Massachusetts, with an operational office in Dallas, Texas, the company is pre-revenue and is advancing its candidates through strategic alliances and a protected IP portfolio.
View full company profileAbout Venturis Therapeutics
Venturis Therapeutics is a private, clinical-stage biotech company leveraging Fibroblast Growth Factor (FGF) proteins to promote blood vessel growth for treating ischemic conditions. Its lead program targets diabetic wounds, coronary heart disease, and peripheral artery disease, with a broader preclinical pipeline exploring applications in erectile dysfunction, stroke, and neurodegenerative diseases. Founded in 2021 and headquartered in Cambridge, Massachusetts, with an operational office in Dallas, Texas, the company is pre-revenue and is advancing its candidates through strategic alliances and a protected IP portfolio.
View full company profileAbout Venturis Therapeutics
Venturis Therapeutics is a private, clinical-stage biotech company leveraging Fibroblast Growth Factor (FGF) proteins to promote blood vessel growth for treating ischemic conditions. Its lead program targets diabetic wounds, coronary heart disease, and peripheral artery disease, with a broader preclinical pipeline exploring applications in erectile dysfunction, stroke, and neurodegenerative diseases. Founded in 2021 and headquartered in Cambridge, Massachusetts, with an operational office in Dallas, Texas, the company is pre-revenue and is advancing its candidates through strategic alliances and a protected IP portfolio.
View full company profileAbout Venturis Therapeutics
Venturis Therapeutics is a private, clinical-stage biotech company leveraging Fibroblast Growth Factor (FGF) proteins to promote blood vessel growth for treating ischemic conditions. Its lead program targets diabetic wounds, coronary heart disease, and peripheral artery disease, with a broader preclinical pipeline exploring applications in erectile dysfunction, stroke, and neurodegenerative diseases. Founded in 2021 and headquartered in Cambridge, Massachusetts, with an operational office in Dallas, Texas, the company is pre-revenue and is advancing its candidates through strategic alliances and a protected IP portfolio.
View full company profileAbout Venturis Therapeutics
Venturis Therapeutics is a private, clinical-stage biotech company leveraging Fibroblast Growth Factor (FGF) proteins to promote blood vessel growth for treating ischemic conditions. Its lead program targets diabetic wounds, coronary heart disease, and peripheral artery disease, with a broader preclinical pipeline exploring applications in erectile dysfunction, stroke, and neurodegenerative diseases. Founded in 2021 and headquartered in Cambridge, Massachusetts, with an operational office in Dallas, Texas, the company is pre-revenue and is advancing its candidates through strategic alliances and a protected IP portfolio.
View full company profile